

What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations?

<https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc300>

Document Type: Table

Review Code: EOC210302 RR Table

Question Submitted: March 30, 2021

Submitted:

Date Completed: April 21, 2021

Status: 3. Completed

Research Team: EOC

Category: Clinical Management
Healthcare Services

Subject: Vaccines
Vaccination
Risk
Comorbidities

Population: All
Other
vulnerable populations (clinically)

Clinical Setting: Cardiac unit
Community
Dialysis unit
ICU
Long Term Care
Medicine Unit
NICU
Oncology
Primary care
Public Health

Priority Level: Level 3 Two weeks (14 days)

Cite As: Azizian, A; Lee, S; Shumilak, G; Groot, G; Reeder, B; Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 20, Document no.: EOC210302 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table).

Similar Reviews: INF031801 RR

Related Documents:

Evidence Search Report: EOC210302 ESR

Rapid Review: EOC210302 RR

Documents



EOC210302 RR
Table

 [Download File](#)